This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Moderna loses bid to dismiss patent case at UPC Hague division

By Inbar Preiss ( May 26, 2025, 12:01 GMT | Insight) -- The Hague Local Division rejected Moderna's preliminary objections on venue and opt-out status, but left the cross-border reach of the Unified Patent Court authority to be decided at trial. The case concerns two Arbutus-owned patents covering technology used in Moderna’s Covid-19 vaccine, and could test the UPC’s ability to assert jurisdiction over non-EU entities for acts outside the territory covered by the UPC Agreement.Moderna has lost its bid to dismiss a Unified Patent Court infringement action brought by Arbutus Biopharma Corporation and Genevant Sciences, after the Hague Local Division rejected the company’s preliminary objections on jurisdiction, venue, and patent opt-out grounds....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections